|Reason for decision
|Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- If you have any queries please email Topic.Selection@nice.org.uk
|31 March 2023
|Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia have been revised. It is anticipated that the appraisal will begin in mid-May 2024 when we will write to you about how you can get involved.
|11 July 2022
|Awaiting development. Status change linked to Topic Selection Decision being set to Selected
For further information on our processes and methods, please see our CHTE processes and methods manual